Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Jun 13, 2005
Appointment of Non-Executive Chairman in Alignment with Good Governance PracticesCAMBRIDGE, Mass., June 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Peter Barrett, Ph.D., a B...
Jun 6, 2005
CAMBRIDGE, Mass., June 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Michael A. Lawless, Senior Director Investor Relations, will present at the 2005 Pacific Growth Equities Life Sci...
May 23, 2005
CAMBRIDGE, Mass., May 23 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced the appointment of Barbara Rosengren as Vice President, Strategic Product Development. Ms. Rosengren will be responsible for ...
May 11, 2005
CAMBRIDGE, Mass., May 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Richard P. Shea, Vice President and Chief Financial Officer, will present at the Banc of America Securities Healt...
May 10, 2005
CAMBRIDGE, Mass., May 10 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced its financial results for the first quarter ended March 31, 2005. For the first quarter 2005, the Company reported a net...
Apr 28, 2005
CAMBRIDGE, Mass., April 28 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan Crane, Chairman and Chief Executive Officer, will present at the Morgan Stanley's Third Annual Global Healthcare Unplug...
Apr 27, 2005
CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Richard Shea, Vice President and Chief Financial Officer, will present at the Second Annual Rodman & Renshaw Techvest Global...
Apr 25, 2005
CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, will report its financial results for the first quarter ended March 31, 2005 before the U.S. financial markets open on Tuesday, May 10, 2005....
Apr 25, 2005
CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced that it will hold its Annual Meeting of Stockholders on May 26, 2005 at 8:30 am EDT at the offices of Wilmer Cutler Pickering Hal...
Apr 25, 2005
CAMBRIDGE, Mass., April 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan Crane, Chairman and Chief Executive Officer, will present at the Deutsche Bank Securities 30th Annual Heal...
FirstPrevious
...
39
NextLast
= add release to Briefcase